522 related articles for article (PubMed ID: 22037472)
1. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene.
Shen C; Beroukhim R; Schumacher SE; Zhou J; Chang M; Signoretti S; Kaelin WG
Cancer Discov; 2011 Aug; 1(3):222-35. PubMed ID: 22037472
[TBL] [Abstract][Full Text] [Related]
2. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
Kroeger N; Klatte T; Chamie K; Rao PN; Birkhäuser FD; Sonn GA; Riss J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
Cancer; 2013 Apr; 119(8):1547-54. PubMed ID: 23335244
[TBL] [Abstract][Full Text] [Related]
3. HIF1α is not a target of 14q deletion in clear cell renal cancer.
Shenoy N
Sci Rep; 2020 Oct; 10(1):17642. PubMed ID: 33077781
[TBL] [Abstract][Full Text] [Related]
4. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.
Monzon FA; Alvarez K; Peterson L; Truong L; Amato RJ; Hernandez-McClain J; Tannir N; Parwani AV; Jonasch E
Mod Pathol; 2011 Nov; 24(11):1470-9. PubMed ID: 21725288
[TBL] [Abstract][Full Text] [Related]
6. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
7. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
8. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
9. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
10. The role of HIF1α in renal cell carcinoma tumorigenesis.
Gudas LJ; Fu L; Minton DR; Mongan NP; Nanus DM
J Mol Med (Berl); 2014 Aug; 92(8):825-36. PubMed ID: 24916472
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
12. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
13. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology.
Thrash-Bingham CA; Salazar H; Freed JJ; Greenberg RE; Tartof KD
Cancer Res; 1995 Dec; 55(24):6189-95. PubMed ID: 8521412
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
15. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
Gao W; Li W; Xiao T; Liu XS; Kaelin WG
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
18. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells.
Harten SK; Esteban MA; Shukla D; Ashcroft M; Maxwell PH
Mol Cancer; 2011 Jul; 10():89. PubMed ID: 21791076
[TBL] [Abstract][Full Text] [Related]
20. HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.
Toschi A; Edelstein J; Rockwell P; Ohh M; Foster DA
Oncogene; 2008 Apr; 27(19):2746-53. PubMed ID: 17998935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]